Preliminary Results of A Phase I/IIA Study of BMS-986156 (GLUCOCORTICOID-Induced Tumour Necrosis Factor Receptor-Related Gene [GITR] AGONIST), Alone and In Combination with Nivolumab in Patients with Advanced Solid Tumours

Lillian L. Siu, Neeltje Steeghs, Tarek Meniawy, Markus Joerger, Jennifer L. Spratlin, Sylvie Rottey, Adnan Nagrial, Adam Cooper, Roland Meier, Yun Shen, Penny Phillips, Gaurav Bajaj, Jochem Gokemeijer, Alan J. Korman, Kyaw L. Aung, Matteo S. Carlino

Research output: Contribution to journalAbstract/Meeting Abstract

Original languageEnglish
Pages (from-to)116-117
Number of pages2
JournalAsia-Pacific Journal of Clinical Oncology
Volume13
Publication statusPublished - Nov 2017

Cite this

Siu, L. L., Steeghs, N., Meniawy, T., Joerger, M., Spratlin, J. L., Rottey, S., Nagrial, A., Cooper, A., Meier, R., Shen, Y., Phillips, P., Bajaj, G., Gokemeijer, J., Korman, A. J., Aung, K. L., & Carlino, M. S. (2017). Preliminary Results of A Phase I/IIA Study of BMS-986156 (GLUCOCORTICOID-Induced Tumour Necrosis Factor Receptor-Related Gene [GITR] AGONIST), Alone and In Combination with Nivolumab in Patients with Advanced Solid Tumours. Asia-Pacific Journal of Clinical Oncology, 13, 116-117.